No Data
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Baird analyst Jack Allen maintains $Mereo BioPharma(MREO.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 32.9% and a total
Mereo BioPharma Group Plc (MREO): A Bull Case Theory
Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Mereo BioPharma CFO Sells Over $121k in Company Stock
No Data
No Data